Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00880334 · ClinicalTrials.gov registry record · Phase 2
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 149
- Enrollment target
NCT00880334 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 149 participants.
The verdict
NCT00880334, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 149 participants
- Enrollment target
Study Summary
In this research study the investigators are looking to see if the combination of docetaxel plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma (TCC). Docetaxel is a chemotherapy drug that kills cancer cells that are dividing. It is widely used in TCC. Vandetanib is a drug that is believed to stop new blood vessels from forming around cancer cells. The combination of docetaxel and Vandetanib has been studied in people with lung cancer and found to be helpful in killing cancer cells. Thus, this study is looking at people with TCC, to see if the combination of docetaxel plus Vandetanib is better or worse then docetaxel alone.
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG vandetanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2006-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00880334
The ClinicalTrials.gov registry entry for NCT00880334 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00880334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00880334 about?
NCT00880334 is a clinical study titled "Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC". In this research study the investigators are looking to see if the combination of docetaxel plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma (TCC). Docetaxel is a chemotherapy drug that kills cancer cells that are dividing. It is widely used in TCC. Vandetanib ...
What is the current status of trial NCT00880334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 149 participants. The study started on 2006-09. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00880334?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), vandetanib (DRUG).
Who is sponsoring clinical trial NCT00880334?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.